The most active researchers, institutions, and subtopics in Multiple Myeloma, from recent PubMed records. Public authorship only, every figure verifiable by PMID.
Analyzed 438 recent PubMed papers (2021-2026) matching "multiple myeloma bispecific CAR-T". Source: NLM PubMed. Generated July 2026.
| # | Researcher | Affiliation | Papers |
|---|---|---|---|
| 1 | Einsele Hermann | University Hospital of Würzburg | 18 |
| 2 | Lin Yi | Mayo Clinic | 11 |
| 3 | Richter Joshua | Tisch Cancer Institute | 11 |
| 4 | Weisel Katja | University Medical Center Hamburg-Eppendorf | 11 |
| 5 | Rasche Leo | University Hospital of Würzburg | 11 |
| 6 | Raza Shahzad | Cleveland Clinic | 11 |
| 7 | Anwer Faiz | Cleveland Clinic | 11 |
| 8 | Banerjee Rahul | Fred Hutchinson Cancer Center | 11 |
| 9 | Chari Ajai | Tisch Cancer Institute | 10 |
| 10 | Dima Danai | Cleveland Clinic | 9 |
| 11 | Abdallah Al-Ola | University of Kansas Medical Center | 8 |
| 12 | Sidana Surbhi | Stanford University School of Medicine | 8 |
| 13 | Al Hadidi Samer | University of Arkansas for Medical Sciences | 8 |
| 14 | Richard Shambavi | Tisch Cancer Institute | 8 |
| 15 | Mei Heng | Union Hospital | 7 |
| 16 | Merz Maximilian | University Hospital Leipzig | 7 |
| 17 | Dhakal Binod | Medical College of Wisconsin | 7 |
| 18 | Khouri Jack | Cleveland Clinic | 7 |
Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.
Frontline T cell-redirecting therapies in newly diagnosed multiple myeloma: key signals from the 2025 ASH Annual Meeting. (2026) · PMID 42477839
BCMA-Targeted Therapy Enables Combined Haploidentical Stem Cell and Kidney Transplantation in a Highly Sensitized Patient. (2026) · PMID 42476317
Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients. (2026) · PMID 42454131
Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigat (2026) · PMID 42449627
Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic (2026) · PMID 42448658
A full Multiple Myeloma brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.